Etanercept is a dimeric fusion protein that serves as a competitive TNF inhibitor by binding to TNF. It effectively inhibits the binding of both TNF-α and TNF-β to the TNF receptors on cell surfaces, thereby rendering TNF biologically inactive. Etanercept has demonstrated efficacy in treating rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.

Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody with affinity for the beta chain of the OSM receptor and inhibition of IL-31 and OSM signaling.Vixarelimab can be used to study severe nodular itch and idiopathic pulmonary fibrosis.

Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model of idiopathic pulmonary fibrosis. Andecaliximab can be used to study gastric adenocarcinoma and idiopathic pulmonary fibrosis (IPF), as well as dengue virus.

Bevifimod (PRTX-100), a highly purified variant of Staphylococcal protein A (SpA), is utilized in research on idiopathic thrombocytopenic purpura (ITP) [1] [2].

Ifabotuzumab (KB004), an IgG1κ antibody, specifically binds to EphA3 (K D =610 pM), inducing tumor cell apoptosis, activating antibody-dependent cell-mediated cytotoxicity (ADCC), and damaging tumor vasculature. Additionally, Ifabotuzumab effectively reduces CCR10+ cells in human idiopathic pulmonary fibrosis (IPF) and ameliorates pulmonary fibrosis, demonstrating its therapeutic potential [1] [2].

Mezagitamab (TAK-079), an IgG1λ anti-CD38 monoclonal antibody, functions by depleting tumor cells that express CD38 through both antibody and complement-dependent cytotoxicity. It shows potential for use in the treatment of relapsed/refractory multiple myeloma (RRMM) and idiopathic thrombocytopenic purpura (ITP) [1] [2] [3].

Begelomab (SAND-26), a murine IgG2b monoclonal antibody targeting DPP-4/CD26, has demonstrated utility in investigating severe refractory idiopathic inflammatory myopathy [1] [2].